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1 Xuedong Wang and Xingang Wu contributed equaBreast cancer resistance protein (BCRP) has been shown to confer multidrug resistance, but the
mechanisms of its regulation are poorly understood. Here, we investigate the effects of wild-type
and mutant p53, and nuclear factor kappa-B (NF-jB) (p50) on BCRP promoter activity in MCF-7 cells.
Our results demonstrated that wild-type p53 markedly suppressed BCRP activity and enhanced the
chemosensitivity of cells to mitoxantrone, whereas mutant p53 had little inhibitory effect. After
inhibition of NF-jB, similar results were obtained. Following knockdown of endogenous p53, BCRP
and p50 expressions were increased, and the chemosensitivity of the cells to mitoxantrone was
decreased. We conclude that wild-type p53 acts as a negative regulator of BCRP gene transcription.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The development of multidrug resistance (MDR) by tumor cells
is a major obstacle to successful chemotherapy for cancer. One piv-
otal mechanism by which tumor cells can become resistant to
cytotoxic drugs used in chemotherapy is the increased expression
of certain ATP-binding cassette (ABC) transporters which including
P-glycoprotein (P-gp, MDR1), multidrug resistance-associated pro-
tein (MRP) and breast cancer resistance protein (BCRP) [1]. These
proteins are thought to function as energy-dependent efﬂux
pumps of a variety of structurally diverse chemotherapeutic
agents, thereby decreasing intracellular drug accumulation. Com-
parison of BCRP protein sequences with that of P-gp and MRP re-
vealed that, unlike P-gp and MRP, which are arranged in two
repeated halves, BCRP is a half-transporter consisting of only one
nucleotide binding domain followed by one membrane-spanning
domain. This cell line (MCF-7/AdrVp) was selected by continuous
exposure to doxorubicin in combination with verapamil to avoid
development of resistance due to expression of P-gp. Interestingly,chemical Societies. Published by E
ATP-binding cassette; BCRP,
stance-associated protein; P-
Ai, RNA interference; wt-p53,
SA, electrophoretic mobility
.
lly to this work.MCF-7/AdrVp cells also did not express the multidrug resistance-
associated protein MRP [2]. BCRP was also discovered by investi-
gating cell lines selected for resistance to mitoxantrone – a poor
substrate for P-gp and MRP, which is a high-afﬁnity substrate for
BCRP [3]. BCRP expression status is a signiﬁcant determinant of
sensitivity of cancer cells to its substrate anticancer agents.
P53 is a critical tumor suppressor in the human cells that medi-
ates growth arrest, senescence and apoptosis in response to several
cellular stresses and often referred to as ‘‘the guardian of the gen-
ome”. Mutations of the p53 tumor suppressor gene have been esti-
mated to occur in close to 50% of human tumors and p53 mutation
is not a random process [4]. According to the p53 mutation data-
base (www.iarc.fr/p53), the majority of DNA mutations are located
in the core domain responsible for DNA binding, such as codons
175, 245, 248, 249, 273, and 282. The hot spot mutations at codons
175 and 248 occur with highest frequency in human cancers. P53
functions primarily as a transcription factor which exerts its down-
stream functions by activating or repressing a large number of its
downstream genes [5,6]. The majority of the promoter studies
seem to conﬁrm a downregulation of the MDR1 or MRP promoter
by wild-type p53 (wt-p53) and an upregulation or activation by
certain mutants of p53 [7,8].
Up to now, whether p53 gene can regulate BCRP gene expres-
sion has not been reported. The mechanisms of BCRP overexpres-
sion in drug-resistant cells are not clearly understood. In this
study, we investigated the role of p53 gene in the regulation of hu-
man BCRP gene expression. Disclosing the relationship betweenlsevier B.V. All rights reserved.
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explanation of the mechanisms of drug resistance.
2. Materials and methods
2.1. Materials
The human breast cancer cell line MCF-7 and JAR (a human cho-
riocarcinoma cell line overexpressing endogeneous BCRP) were
purchased from Type Culture Collection of Chinese Academy of Sci-
ences (Shanghai, China). The wild type (wt) p53 expression plas-
mid, pC53-SN3, and the empty vector, the mutants of pC53–175
and pC53–248 were kindly provided by Dr. Liang Cao at the Uni-
versity of Hong Kong of China and their constructions have been
described elsewhere [9]. Plasmid pAVU6 + 27 (a gift of Dr. ML He,
University of Hong Kong, China) was used to generate a plasmid
that expressing hairpin RNAs. The nuclear factor kappa-B (NF-jB)
promoter/luciferase reporter plasmid (pNF-jB) was a gift of Dr.
Cao L (University of Hong Kong, China) [10]. pBabe-IjBa was con-
structed by IjBamutant gene into EcoRI sites of retroviral plasmid
pBabe.
2.2. Constrution of BCRP promoter-luciferase plasmids
Genomic DNA was extracted from the human JAR cells using a
QIAamp DNAMini Kit (Qiagen, Hilden, Germany). The promoter re-
gion of the human BCRP gene, a 358 bp fragment was ampliﬁed by
PCR using the following primers: 50-CCGCTCGAGGAGGTACT GAT-
CAGCCCAATGAG-30 and 50-CCCAAGCTTAGCGCTGACACGAACTTCC-
TAAG-30. The promoter fragment was cloned into the Hind III and
Xbal I sites in the pGL2-Basic (Promega, Madison, WI). All of the
constructed DNAs were puriﬁed through Qiagen columns (Qiagen)
and conﬁrmed by restruction analysis and sequencing.
2.3. Generation and characterization of p53-overexpression cell lines
MCF-7/wtp53
The MCF-7 cells were plated in the wells of a 6-well plates at a
density of 1.0  105 cells per well and incubated overnight to
90  95% conﬂuent and transfected with 5.0 lg of wt-p53 expres-
sion plasmid DNA or the empty vector DNA for pCMV-Neo-Bam by
using Lipofectamine 2000 kit (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Forty-eight hours
after transfection, G418 (800 lg/ml) was added to the medium
and was supplemented in the media throughout the cloning pro-
cess. After growing the cells in the presence of G418 for 3 weeks,
a few colonies formed in plates transfected with p53 plasmids,
compared with about 100 times more colonies with empty vector
transfection. Individual colonies were isolated with a cloning ring
from the transfection plates and expanded as established cell lines
(MCF-7/wtp53, and MCF-7/pCMV). Other cell lines established
similar to the above method.2.4. Transient transfection and luciferase reporter gene assays
MCF-7 cells were plated in the wells of a 24-well plates at a
density of 1.0  105 cells per well and incubated overnight to
90  95% conﬂuent. Using Lipofectamine 2000 kit (Invitrogen) as
instructed by the manufacturer, plasmid DNA (2.0 lg) and DNA
for cotransfection were transfected into the cells. Luciferase plas-
mids were cotransfected with 1.0 lg b-galactosidase or Renilla
control vector (Promega) to monitor transfection efﬁciency. For
luciferase assays, cells were washed three times with 2.0 ml
of ice-cold phosphate balanced solution (PBS) and were lysed
in 150 ll of lysis buffer. Samples were assayed in a Lumi-ScintLuminometer (Bioscan, Washington, USA) using 20 ll of cell lysate
and 100 ll of Luciferase assay reagent (Promega). Luciferase activ-
ity was measured a 10 s delay and 30 s integration time and was
normalized to b-galactosidase or Renilla luciferase activity to
determine transfection efﬁciency.
2.5. Transfection of RNA interference plasmid
The short-hairpin-RNA-encoding complementary single-
stranded oligonucleotides corresponding to p53 were designed
according to the literatures [11]. These oligonucleotides 50-tcgac-
GACTCCAGTGGTAATCTACttcaagagaGTAGATTACCACTGGAGTCttttt-
30 and 50-ctagaaaaaGACTCCAGTGGTAATCTACtctcttgaaGTAGATTAC-
CACTGGAGTCG-30; 50-tcgacAGCTTCATAAGGCGCATGCttcaagagaG-
CATGCGCCTTATGAAGCTttttt-30 and 50-ctagaaaaaAGCTTCATAAGG-
CGCATGCtctcttgaaGCATGCGCCTTATGAAGCTG-30, were annealed
and cloned into pAVU6+27 vector to generate p53 (pAVU6 + 27/
sip53) and control construction (pAVU6+27/sicontrol), respectively.
Then, MCF-7 cells were transfected with the above constructions
using Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s protocol.
2.6. RNA extraction and reverse transcription polymerase chain
reaction (RT-PCR) assay
Total cellular RNA was isolated from cells using TRIzol reagent
(Invitrogen) and quantiﬁed by UV absorbance spectroscopy. BCRP,
NF-jB (p50), b-actin mRNA transcripts were detected using RT-
PCR assays. A 206 bp BCRP cDNA fragment was ampliﬁed with
the primers 50-CACCTTATTGGCCTCAGGAA-30 (sense) and 50-
CCTGCTTGGAAGGCTCTATG-30 (antisense); a 176 bp NF-jB (p50)
cDNA fragment with the primers: 50-CTGGAAGCACGAATGACAGA-
30 (sense) and 50-TGAGGTCCATCTCCTTGGTC-30 (antisense); a
194 bp p53 cDNA fragment with the primers: 50-CCAGCCAAAGAA-
GAAACCAC-30 (sense) and 50-TATGGCGGGAGGTAGACTGA-30 (anti-
sense). As an internal control, ampliﬁcation of b-actin mRNA
(309 bp) was carried out with the primers 50-ACCGTGGAGAAGAGC-
TACGA-30 (sense) and50-GTACTTGCGCTCAGAAGGAG-30 (antisense).
2.7. Western blot and electrophoretic mobility shift assays (EMSA)
Western blotting and EMSA analyses were carried out as previ-
ously described [12,13]. Biotin-labeled double-strand NF-jB
oligonucleotides (50-CCCGACCTGGGGAAACCCGGGCGCTGGGG-30)
containing the NF-jB (p50) binding site in the BCRP promoter
and mutant NF-jB oligonucleotides (50-CCCGACCTTTTTTA-
ATTTGGGGCGCTGGGG-30) were obtained from Zhaorui Biotech
Co., Ltd. (Shanghai, China) and used as probes (underlining indi-
cates NF-jB binding site).
2.8. Chromatin immunoprecipitation assay (ChIP)
Immunoprecipitation experiments with an anti- NF-jB (p50)
antibody (Santa Cruz Biotech., CA) to examine protein-DNA interac-
tionswere done using the chromatin immunoprecipitation assay kit
(Upstate, Charlottesville, VA) followingmanufacturer’s instructions.
To analyze the target regions (NF-jB-binding site at 27/18 re-
gions in the BCRP promoter), the DNA samples were ampliﬁed by
PCR, forward; 50-CGGGAGTGTTTGGCTTGTC-30; reverse: 50-CAGA-
GCTGAACGCAGTGGC-30 that generated a 233-bp PCR product.
2.9. Cytotoxicity assay
Cytotoxicity of mitoxantrone on cells was assessed by MTT as
described previously [14]. Cells were counted and then cultured
in 96-wells plate, and treated with those anticancer drugs of
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absorption of untreated cells was normalized to 1. The anti-prolif-
erative effects of the drugs were evaluated by survival rate. Fifty
percent cell growth inhibitory concentrations (IC50) were calcu-
lated from linear regression analysis of the linear portion of the
growth curves.
2.10. Statistical analysis
For all statistical tests, the SPSS-11.0 version software package
(SPSS Inc., Cary, USA) was used. All data are expressed as the
mean ± S.D. from three or more experiments. Statistical analyses
of the data were carried out using the Student’s Z-test with
P < 0.05 considered as statistically signiﬁcant.
3. Results
3.1. Wt-p53 but not mutant p53 inhibits BCRP expression in MCF-7
cells
As shown in Fig. 1A and B, MCF-7/wt-p53 cell line overexpres-
sed p53 mRNA, as determined by RT-PCR, compared with MCF-7
cell line and empty vector-transfected cell line, MCF-7/pCMV.
Expression of the p53 protein in the MCF-7/wt-p53 cell line was
conﬁrmed by Western blot analysis. Of importance, in the MCF-
7/wt-p53, there was a decrease in BCRP transcripts compared withFig. 1. Effects of p53 on BCRP expression and promoter activity. (A) By RT-PCR assay, the
7/pCMV. Between MCF-7/wt-p53 and mutant p53 cells, there were no markedly changes
increased and p53 was decreased. b-Actin was used as an internal control. MCF-7 cells w
experiments. (B) By Western blot assay, similar results were obtained. (C) Survival curves
were seeded at a density of 104 cells per well in 96-well plates and then incubated for 48
was assessed by the MTT assay. Data points represent means from various kinds of cells in
different dose (0.1 lg, 0.3 lg, 0.5 lg, respectively) of p53 expression plasmids (pC53-SN3)
after 48 h of transfection and normalized by b-galactosidase activity. Values are expressed
were not transfected with p53 expression plasmid. Values are mean ± S.D. (n = 3). StatisMCF-7 cell line and empty vector-transfected cell line, MCF-7/
pCMV, suggesting that exogenous expression of wt-p53 inhibited
endogenous BCRP transcription in MCF-7 cells. Contrary to the
MCF-7/wt-p53 cells, there were no markedly changes in BCRP
mRNA and protein levels in mutant p53 overexpression cell lines.
To further deﬁne the effects of endogenous p53 on BCRP expres-
sion, MCF-7 cells were transfected with p53 knockdown constructs
(pAVU6/sip53) or control constructs (pAVU6/sicontrol). As shown
in Fig. 1A and B, the endogenous p53 expression in MCF-7 was dis-
rupted after transfected with pAVU6/sip53. Whereas, there were
increases in BCRP mRNA and protein levels in MCF-7/sip53.
To know whether expression of wild-type p53 can enhance
chemosensitivity, we detected cells survival rate on various kinds
of cells after the different concentrations of drugs treated.
As shown in Fig. 1C, the chemosensitivity of MCF-7/wt-p53 to
mitoxantrone was enhanced, which might predict that the level
of BCRP was decreased. However, there were no signiﬁcant
changes on the mutant p53 overexpression cell lines chemosensi-
tivity to mitoxantrone. The endogenous p53 expression in MCF-7
was disrupted by RNA interference (RNAi). The survival rate of
endogenous p53 silencing cells treated with mitoxantrone in-
creased signiﬁcantly.
IC50 valueswere calculated in accordancewith the survival curve
(Fig. 1C). The IC50 in MCF-7/pCMV, MCF-7/wt-p53, MCF-7/p53R175H
and MCF-7/p53R248W cells under mitoxantrone condition was
0.654 ± 0.043 lmol/L, 0.174 ± 0.012 lmol/L, 0.652 ± 0.038 lmol/Lre was an increase in p53 expression on the MCF-7/wt-p53 compared with the MCF-
on p53 in mRNA levels. After transfected with MCF-7/si p53, BCRP expression was
ere used as control. The data shown are representative of three to four independent
of various kinds of cells after the different concentrations of drugs treated. The cells
h in the presence or absence of increasing mitoxantrone concentrations. Cell survival
three independent experiments; bars, S.D. (D) MCF-7 cells were cotransfected with
and BCRP luciferase promoter reporter constructs. Luciferase activity was measured
as the percentage of the control activity (100%) in cell extract fromMCF-7 cells that
tical signiﬁcance compared with control: *P < 0.05, **P < 0.01.
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p53 cells to mitoxantrone increased 3.76 times (compared with
MCF-7/pCMV), while the sensitivity of mutant p53 to mitoxantrone
had no signiﬁcant change. After knocking down endogenouswt-p53
through RNAi, the IC50 in MCF-7/control and MCF-7/RNAi cells was
0.515 ± 0.138 lmol/L and 1.378 ± 0.512 lmol/L, respectively. The
resistanceofMCF-7/RNAi cells tomitoxantrone increased2.68 times
(compared with MCF-7/control).
To test the effect of exogenous p53 onBCRP transcription inMCF-
7 cells, the experiments were conducted inMCF-7 cells by co-trans-
fecting the wt-p53 expression plasmids with the BCRP luciferase
promoter reporter constructs. As shown in Fig. 1D, the wt-p53
expression plasmid causedmarked inhibition of the BCRP promoter
activity in a dose-dependentmanner,with 67.7% inhibition at a dose
of 0.5 lg. In contrast to wt-p53, mutant p53with eithermutation in
protein-binding region (p53R175H) or mutation in DNA-binding re-
gion (p53R248W) of p53 protein lost most of the inhibitory effect of
wt-p53. The inhibition of BCRP promoter activity is speciﬁc because
expression of p53 had no inhibitory effect on the empty luciferase
vectors.
3.2. Wt-p53 but not mutant p53 inhibits NF-jB subunit p50 expression
in MCF-7 cells
To deﬁne the effects of p53 on NF-jB expression, we co-trans-
fected the p53 expression plasmids with the NF-jB luciferase pro-
moter reporter constructs. As shown in Fig. 2A, wt-p53 inhibited
NF-jB promoter activity in a concentration-dependent manner,
with 79.6% inhibition at a dose of 0.5 lg. Contrary to wt-p53, mu-
tant p53 with either mutation in protein-binding region (p53R175H)
or mutation in DNA-binding region (p53R248W) of p53 protein lost
the effect.
To further determine whether NF-jB is involved in the tran-
scriptional suppression of the BCRP gene by p53 in MCF-7 cells,
we performed RT-PCR and Western blot to assess the levels of
NF-jB in p53 overexpression cells. Results showed that NF-jB
was downregulated in MCF-7/wt-p53 cells. In contrast to the
MCF-7/wt-p53 cells, there were no markedly changes in the levels
of NF-jB (p50) mRNA and protein in mutant p53 overexpression
cell lines (Fig. 2B and C). When endogenous p53 expression in
MCF-7 was disrupted by RNA interfere, NF-jB expression was
upregulated.Fig. 2. Effects of p53 on NF-jB expression and promoter activity. (A) MCF-7 cells were cot
plasmids (pC53-SN3) and NF-jB luciferase promoter reporter constructs. Luciferase activ
activity. Values are expressed as the percentage of the control activity (100%) in cell extr
are mean ± S.D. (n = 3). Statistical signiﬁcance compared with control: *P < 0.05, **P < 0.01
with the MCF-7/pCMV. Between MCF-7/wt-p53 and mutant p53 cells, there were mar
expression was increased. b-actin was used as an internal control. MCF-7 cells were used
(C) By Western blot assay, similar results were obtained.3.3. Suppression of BCRP by wt-p53 in MCF-7 cells may be dependent
of NF-jB
To assess the hypothesis that NF-jB plays a role in p53-
mediated suppression of BCRP, we transfected MCF-7 cells with
different dose of a dominant-negative IjBa mutant expression
plasmid to obtain cells with different NF-jB activity. Meanwhile,
wt-p53 expression plasmid and BCRP luciferase promoter reporter
construct were co-transfected. The results showed a lower inhibi-
tory effect of wt-p53 on BCRP promoter activity after inhibition of
NF-jB activity (Fig. 3A). These data demonstrated that NF-jB
might play a role in p53-mediated repression of BCRP.
To investigate the effects of IjBa on the regulation of BCRP
expression, we established IjBa overexpression cell lines, MCF-7/
IjBa and JAR/IjBa cells. RT-PCR and Western blot asssays were
enformed to conﬁrm the levels of BCRP mRNA and protein. As
shown in Fig. 3B and C, there was a decrease in BCRP expression
in MCF-7/IjBa and JAR/IjBa cells lines, compared with MCF-7
cells (mock) and empty vector-transfected cell line, MCF-7/pBabe
or JAR/pBabe (vector).
3.4. NF-jB activates BCRP expression by directly binding to BCRP
promoter
To investigate the effects of NF-jB on BCRP expression, we then
constructed three plasmids, in which BCRP/promoter was inserted
into the pGL3 and NF-jB-p50 as well as NF-jB-p65 was inserted
into the pcDNA3.1, respectively. As shown in Fig. 4A. Co-transfect-
ing with pcDNA3.1-p50 and pcDNA3.1-p65 respectively, the activ-
ities of pGL3-BCRP/promoter are approximately 1.5-fold and
1.1-fold higher than basal activity of the pGL3-BCRP/promoter,
indicating that NF-jB plays a regulatory role for the activities of
the BCRP promoter.
To further determine the possibility of NF-jB binding to BCRP
promoter binding site, EMSA was done with speciﬁc oligonucleo-
tides and mutant oligonucleotides. Fig. 4B shows efﬁcient binding
to the radiolabeled speciﬁc oligonucleotides. NF-jB (p50) can be
combined with speciﬁc oligonucleotide probes but not with the
mutant oligonucleotide probes. This combination can be competi-
tively inhibited by 100-fold unlabeled speciﬁc oligonucleotides
but not be inhibited by 100-fold unlabeled non-speciﬁc oligo-
nucleotides. These results suggest that BCRP promoter has speciﬁcransfected with different dose (0.1 lg, 0.3 lg, 0.5 lg, respectively) of p53 expression
ity was measured after 48 hours of transfection and normalized by b-galactosidase
act from MCF-7 cells that were not transfected with p53 expression plasmid. Values
. (B) By RT-PCR assay, there was a decrease in NF-jBon the MCF-7/wt-p53 compared
kedly changes on NF-jB in mRNA levels. After transfected with p53siRNA, NF-jB
as control. The results shown are representative of three independent experiments.
Fig. 3. Effects of IjBa on BCRP expression and promoter activity. (A) MCF-7 cells were transfected with various amounts of a dominant-negative IjBa mutant expression
plasmid (pBabe-IjB) to obtain cells with different NF-jB activity. These cells were cotransfected with wt-p53 expression plasmids (or empty vectors) and BCRP luciferase
promoter reporter constructs. Values are the means of the relative luciferase activity, normalized to b-galactosidase activity, from three separate experiments; bars, S.D.
Statistical signiﬁcance compared with control: *P < 0.05, **P < 0.01. (B) MCF-7 cells and JAR cells were transfected with pBabe/IjBa. By RT-PCR assay, there was a decrease in
BCRP expression on the MCF-7/IjBa or JAR/IjBa cells compared with the MCF-7/vector or JAR/vector cells. b-actin was used as an internal control. MCF-7 cells were used as
control or mock. Quantitative data from three independent experiments were shown in right panel. (C) By Western blot assay, similar results were obtained.
Fig. 4. Effects of NF-jB on BCRP promoter activity and p50 binding site assay. (A) MCF-7 cells were transiently transfected with pcDNA3.1-p65 (100 ng), pcDNA3.1-p50
(100 ng), pGL3-BCRP/promoter (100 ng), pcDNA3.1-p65 + pGL3-BCRP/promoter (100 ng) and pcDNA3.1-p50 (100 ng) + pGL3-BCRP/promoter (100 ng), respectively. Cells
were also transfected with empty pGL3 (100 ng) as negative control. All luciferase assay results expressed as relative luciferase activity (i.e., ﬁreﬂy luciferase light units/
Renilla luciferase light units). The results were quantiﬁed based on three experiments and are presented as mean ± S.D. Statistical signiﬁcance compared with pGL3-BCRP/
promoter group: *P < 0.01. (B) Electrophoretic mobility shift assay of NF-jB (p50) binding site within the BCRP promoter. Lane 1: negative control, the reaction mixture of the
biotin-labeled speciﬁc oligonucleotides and mutant oligonucleotides; lane 2: labeled speciﬁc oligonucleotides and nuclear extracts; lane 3: labeled mutant oligonucleotides
and nuclear extracts; lane 4: labeled speciﬁc oligonucleotides and 100-fold excess amounts of unlabeled speciﬁc oligonucleotides added to nuclear extracts; lane 5: labeled
speciﬁc oligonucleotides and 100-fold excess amounts of unlabeled mutant oligonucleotides added to nuclear extracts. ‘‘S” indicates the speciﬁcally shift band, while ‘‘P”
indicates free probe. The representative experiment out of the three experiments is shown. (C) Chromatin immunoprecipitation assay was performed using anti-NF-jB (p50)
or Normal Mouse IgG. PCR primers covering the NF-jB (p50) binding sites of BCRP promoter region were used to detect promoter fragment resulting from the 215 to +18
promoter regions in immunoprecipitates. Input is DNA that had been processed as samples but without any immunoprecipitation and was used as a PCR positive control. The
negative control is Normal Mouse IgG, which controls for the non-speciﬁc immunoselection of chromatin by immunoglobulins. Control Primers are included for detection of a
166 base pair region of the human GAPDH promoter. The experiment shown is representative of three.
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interacts with the endogenous BCRP promoter in MCF-7cells, weperformed chromatin immunoprecipitation using anti-NF-jB
(p50). We detected a speciﬁc band after PCR on the MCF-7
X. Wang et al. / FEBS Letters 584 (2010) 3392–3397 3397immunoprecipitate with oligonucleotides corresponding to the
215 to +18 BCRP promoter regions (Fig. 4C).
4. Discussion
We have demonstrated in this study that the human BCRP gene
is negatively regulated at the transcriptional level by wt-p53. This
inhibitory effect on BCRP gene expression by wt-p53 is due at least,
in part, to attenuating the effect of a powerful transcription activa-
tor, NF-jB. Our data presented here strongly support the conclu-
sion that BCRP expression is transcriptionally downregulated by
wt-p53 but not mutant p53 in MCF-7 cells. First, the overexpres-
sion of wt-p53 decreased BCRP expression at the mRNA and
protein levels, but the mutant p53 with either mutation in pro-
tein-binding region (p53R175H) or mutation in DNA-binding region
(p53R248W) lost this inhibitory effect. Second, after the endogenous
wt-p53 was disrupted by RNAi, the BCRP expression was upregu-
lated. Third, cotransfection of the p53 expression plasmids and
BCRP promoter into MCF-7 cells also demonstrated the ability of
p53 to regulate the BCRP promoter. Furthermore, to investigate
the effect of p53 gene on BCRP gene expression, we established sev-
eral stable cell lines with overexpression of exogenous wild-type,
MCF-7/wt-p53 and mutant type p53, MCF-7/p53R175H and MCF-
7/p53R248W and found the chemosensitivity of MCF-7/wt-p53 to
mitoxantrone, which is a speciﬁc substrate of BCRP, was enhanced.
Using the MatInspector program [15] with a core similarity of
1.0 and a matrix similarity of at least 0.85, we did not ﬁnd any
potential p53 consensus binding sites within the BCRP promoter,
but a potential NF-jB (p50) binding site. Moreover, we were un-
able to detect p53 direct interaction with BCRP promoter using
EMSA assay (data not shown). It seems likely that p53 may
mediate the repression through an indirect mechanism rather
than direct DNA binding. We found that NF-jB activated BCRP
expression through binding to the speciﬁc NF-jB (p50) site
(27/18) within BCRP promoter. Our results indicate that p53
represses BCRP through an indirect mechanism involving the
binding of NF-jB to BCRP promoter in MCF-7 cells, at least in
part. This interpretation is supported by the following evidences:
ﬁrst, p53 does not direct interact with BCRP promoter; second,
NF-jB can bind to BCRP promoter and increase BCRP expression;
third, in MCF-7 cells, both overexpression of wt-p53 and inhibi-
tion of NF-jB decrease BCRP promoter activity, and after inhibi-
tion of NF-jB by IjBa mutant or MG132, the inhibitory effect of
wt-p53 on BCRP promoter activity is lower; forth, in Saos-2 cells,
p53 induces NF-jB activity and p53 also increases BCRP pro-
moter activity (data not shown).
The interactions between p53 and its downstream genes are
mainly through binding to a speciﬁc DNA responsive element. Sev-
eral human genes whose expression is positively regulated by
wild-type p53 have been identiﬁed [16,17]. Additionally, results ob-
tained fromexperiments performedonNF-jB in virally transformed
or p53-null cells might differ if performed in cell lines capable of
mounting a wild-type p53 response. Furthermore, it is possible that
novel cancer therapies based on reactivation of wild-type p53 func-
tionmight beneﬁt from coordinate suppression of NF-jB in order to
promote a beneﬁcial outcome.Wehave also shown thatmutant p53
do not inhibit NF-jB gene expression and it is worth noting that
many previous experiments on NF-jB transcriptional regulation
have been performed in cell lines with mutated p53 or in which it
has been functionally inactivated due to the expression of viral pro-
teins. Previous studies have suggested that wt-p53 inhibits MDR1
and MRP gene expression and the inactivation of wt-p53 led to in-
creased expression of the MDR1 and MRP and drug resistance [18].
However, little is known about the molecular mechanisms regulat-
ing BCRP expression. Here, for the ﬁrst time, we have demonstratedthat BCRP gene expression is also under the negative control of wt-
p53. In the present study, our results show that wt-p53 can inhibit
BCRP gene expression by antagonizing the transactivating effect of
NF-jB subunits p50 on BCRP promoter. We suggest that the break-
down of this pathwaymay result in BCRP overexpression and devel-
opment of BCRP-associated MDR in tumors.
In conclusion, we present that BCRP expression is activated by
NF-jB through direct DNA binding and downregulated by wt-
p53 through a decrease of NF-jB activity in MCF-7 cells. Given that
BCRP account for the atypical multidrug resistance and p53 plays
important role in tumor development, our data should contribute
to a better understand of not only regulation of BCRP, but also can-
cer multidrug resistance (MDR) especially the relationship be-
tween MDR and the development of tumor.
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